USC.edu
Are You a Patient?

Mark Agulnik, MD

Professor of Clinical Medicine

Vice Chair for Faculty Development, Department of Medicine

Section Chief of Sarcomas & Melanoma

Image of Mark Agulnik, MD
Is this your profile? Click to edit
Request an Appointment
Email [email protected]
CTSI Profile

Publications

  • Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J Immunother Cancer. 2021 08; 9(8).. View in PubMed
  • An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021 09; 154:201-208.. View in PubMed
  • The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. Front Oncol. 2021; 11:649963.. View in PubMed
  • Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2022 04 20; 40(12):1291-1300.. View in PubMed
  • Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 08; 125(4):528-533.. View in PubMed
  • Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. Oncologist. 2021 07; 26(7):549-553.. View in PubMed
  • Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.. View in PubMed
  • A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020 09; 137:1-9.. View in PubMed
  • A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. Cancers (Basel). 2020 Jul 11; 12(7).. View in PubMed
  • Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. Cancer Med. 2020 02; 9(3):882-893.. View in PubMed

Similar People